Results 231 to 240 of about 3,144,476 (264)
RETRACTION: Circular RNA circFBXO11 Modulates Hepatocellular Carcinoma Progress and Oxaliplatin Resistance Through miR-605/FOXO3/ABCB1 Axis. [PDF]
J Cell Mol Medeuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Gastric Cancer, 2021
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada +13 more
openaire +2 more sources
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada +13 more
openaire +2 more sources
MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells
Cell Biochemistry and Biophysics, 2020We aimed to understand the molecular mechanism underlying the incidence of Oxaliplatin resistance in colorectal cancer. The Oxaliplatin-resistant (OR) HT29 colorectal cell line was established by long-term exposure to Oxaliplatin. Cell viability and proliferation were determined by the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide and ...
Zhicheng Zhao, Guojing Zhang, Weidong Li
openaire +2 more sources
The cellular pharmacology of oxaliplatin resistance
European Journal of Cancer, 2002Oxaliplatin is a third generation platinum compound that differs from cisplatin and carboplatin in having a broader spectrum of antitumour activity. Molecular studies suggest that oxaliplatin adducts are recognised and processed differently than those produced by the earlier generation Pt-containing drugs.
M, Mishima +4 more
openaire +2 more sources
Bioorganic Chemistry, 2021
Oxaliplatin-based chemotherapy is the current standard of care in adjuvant therapy for advanced colorectal cancer (CRC). But acquired resistance to oxaliplatin eventually occurs and becoming a major cause of treatment failure. Thus, there is an unmet need for developing new chemical entities (NCE) as new therapeutic candidates to target chemotherapy ...
Yaru, Li +7 more
openaire +2 more sources
Oxaliplatin-based chemotherapy is the current standard of care in adjuvant therapy for advanced colorectal cancer (CRC). But acquired resistance to oxaliplatin eventually occurs and becoming a major cause of treatment failure. Thus, there is an unmet need for developing new chemical entities (NCE) as new therapeutic candidates to target chemotherapy ...
Yaru, Li +7 more
openaire +2 more sources
JBIC Journal of Biological Inorganic Chemistry, 2017
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V. +3 more
openaire +2 more sources
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V. +3 more
openaire +2 more sources
Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells
Cancer Letters, 1996Elevation of glutathione (GSH) is commonly observed in cellular resistance to a number of anticancer agents. Most frequently reported change in GSH metabolism that is associated with the elevated GSH levels is increased mRNA expression and activity of gamma-glutamyl cysteine synthetase (gamma GCS), the first enzyme of the GSH biosynthetic pathway.
Z, el-akawi +6 more
openaire +2 more sources
Anticancer Research, 2023
Background/Aim: Antitumor drug resistance is a major hurdle in treating patients with malignant tumors. Casein kinase 2α (CK2α) expression is highly enhanced in oxaliplatin-resistant CRC cells.
C. Yun, J. H. Lee, Sang Hun Lee
semanticscholar +1 more source
Background/Aim: Antitumor drug resistance is a major hurdle in treating patients with malignant tumors. Casein kinase 2α (CK2α) expression is highly enhanced in oxaliplatin-resistant CRC cells.
C. Yun, J. H. Lee, Sang Hun Lee
semanticscholar +1 more source
In vitro studies on the mechanisms of oxaliplatin resistance
Cancer Chemotherapy and Pharmacology, 2001We have previously reported that elevation of glutathione mediated by gamma-glutamyl transpeptidase is one mechanism of oxaliplatin resistance. This study explored other potential oxaliplatin resistance mechanisms with two aims: (1) to identify the differences between cisplatin and oxaliplatin in terms of drug accumulation, DNA-Pt adduct formation and ...
S, Hector +4 more
openaire +2 more sources